Search

Vivian C. Chin

Supervisory Patent Examiner (ID: 17044, Phone: (571)272-7848 , Office: P/2654 )

Most Active Art Unit
2747
Art Unit(s)
2654, 2644, 2695, 2605, 2747, 2608, 2743, 2615, 2614, 2609, 2682
Total Applications
608
Issued Applications
319
Pending Applications
136
Abandoned Applications
157

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18754011 [patent_doc_number] => 20230357374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 18/048386 [patent_app_country] => US [patent_app_date] => 2022-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048386 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/048386
THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS Oct 19, 2022 Pending
Array ( [id] => 19479463 [patent_doc_number] => 20240327505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => ANTIBODIES TO CORONAVIRUS SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 18/703646 [patent_app_country] => US [patent_app_date] => 2022-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18703646 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/703646
ANTIBODIES TO CORONAVIRUS SARS-COV-2 Oct 19, 2022 Pending
Array ( [id] => 18295523 [patent_doc_number] => 20230105209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/937744 [patent_app_country] => US [patent_app_date] => 2022-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937744 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/937744
Antibody specific to spike protein of SARS-CoV-2 and uses thereof Oct 2, 2022 Issued
Array ( [id] => 19731131 [patent_doc_number] => 12209122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Anti-TNF-alpha-antibodies and functional fragments thereof [patent_app_type] => utility [patent_app_number] => 17/958759 [patent_app_country] => US [patent_app_date] => 2022-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 26116 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17958759 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/958759
Anti-TNF-alpha-antibodies and functional fragments thereof Oct 2, 2022 Issued
Array ( [id] => 18932304 [patent_doc_number] => 11884711 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Fusion proteins of GDF15 and use thereof [patent_app_type] => utility [patent_app_number] => 17/935134 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 17547 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935134 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/935134
Fusion proteins of GDF15 and use thereof Sep 25, 2022 Issued
Array ( [id] => 18582912 [patent_doc_number] => 20230265169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/952308 [patent_app_country] => US [patent_app_date] => 2022-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17952308 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/952308
Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof Sep 24, 2022 Issued
Array ( [id] => 18468893 [patent_doc_number] => 20230203176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Methods For Prevention Of Graft Rejection In Xenotransplantation [patent_app_type] => utility [patent_app_number] => 17/946917 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946917 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/946917
Methods For Prevention Of Graft Rejection In Xenotransplantation Sep 15, 2022 Abandoned
Array ( [id] => 20077597 [patent_doc_number] => 12351647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Binding agent and assay for PIVKA [patent_app_type] => utility [patent_app_number] => 17/821937 [patent_app_country] => US [patent_app_date] => 2022-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15710 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821937 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/821937
Binding agent and assay for PIVKA Aug 23, 2022 Issued
Array ( [id] => 18597264 [patent_doc_number] => 20230272059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/890857 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 348 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890857 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/890857
Anti-TNF-alpha-antibodies and functional fragments thereof Aug 17, 2022 Issued
Array ( [id] => 18141449 [patent_doc_number] => 20230015291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/819006 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819006 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/819006
DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS Aug 10, 2022 Abandoned
Array ( [id] => 19738349 [patent_doc_number] => 12215167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-tissue factor antibodies, antibody-drug conjugates, and related methods [patent_app_type] => utility [patent_app_number] => 17/877853 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 88 [patent_no_of_words] => 107500 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877853 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/877853
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods Jul 28, 2022 Issued
Array ( [id] => 19731132 [patent_doc_number] => 12209123 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases [patent_app_type] => utility [patent_app_number] => 17/814075 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 68 [patent_no_of_words] => 26148 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814075 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/814075
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases Jul 20, 2022 Issued
Array ( [id] => 18228932 [patent_doc_number] => 20230067926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION [patent_app_type] => utility [patent_app_number] => 17/868422 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17868422 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/868422
SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION Jul 18, 2022 Pending
Array ( [id] => 18077402 [patent_doc_number] => 20220403014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => COMPOSITIONS AND METHODS OF TREATING THROMBOSIS [patent_app_type] => utility [patent_app_number] => 17/846697 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846697 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/846697
COMPOSITIONS AND METHODS OF TREATING THROMBOSIS Jun 21, 2022 Abandoned
Array ( [id] => 18141339 [patent_doc_number] => 20230015181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/843777 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46513 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843777 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/843777
Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof Jun 16, 2022 Pending
Array ( [id] => 18207374 [patent_doc_number] => 20230053631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ANTIBODIES TO LILRB2 [patent_app_type] => utility [patent_app_number] => 17/838426 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838426 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/838426
ANTIBODIES TO LILRB2 Jun 12, 2022 Abandoned
Array ( [id] => 17990198 [patent_doc_number] => 20220356235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/829688 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829688 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/829688
FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF May 31, 2022 Pending
Array ( [id] => 18125821 [patent_doc_number] => 20230011438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/826932 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826932 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/826932
CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF May 26, 2022 Pending
Array ( [id] => 18094655 [patent_doc_number] => 20220412996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => BLOOD FACTOR MONITORING ASSAY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/749834 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749834 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/749834
BLOOD FACTOR MONITORING ASSAY AND USES THEREOF May 19, 2022 Pending
Array ( [id] => 19692902 [patent_doc_number] => 20250011447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/256316 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256316 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/256316
BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF May 4, 2022 Pending
Menu